OPKO Health (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 10,000 shares of OPKO Health stock in a transaction that occurred on Friday, June 15th. The shares were acquired at an average cost of $4.42 per share, with a total value of $44,200.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $13,564,763.42. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, June 11th, Phillip Md Et Al Frost bought 10,000 shares of OPKO Health stock. The shares were acquired at an average cost of $4.22 per share, with a total value of $42,200.00.
  • On Wednesday, June 6th, Phillip Md Et Al Frost bought 30,000 shares of OPKO Health stock. The shares were acquired at an average cost of $4.05 per share, with a total value of $121,500.00.
  • On Thursday, May 31st, Phillip Md Et Al Frost bought 3,900 shares of OPKO Health stock. The shares were acquired at an average cost of $3.76 per share, with a total value of $14,664.00.
  • On Friday, May 25th, Phillip Md Et Al Frost bought 10,000 shares of OPKO Health stock. The shares were acquired at an average cost of $3.70 per share, with a total value of $37,000.00.
  • On Wednesday, May 23rd, Phillip Md Et Al Frost acquired 40,000 shares of OPKO Health stock. The stock was purchased at an average cost of $3.73 per share, with a total value of $149,200.00.
  • On Monday, May 21st, Phillip Md Et Al Frost acquired 90,000 shares of OPKO Health stock. The stock was purchased at an average cost of $3.82 per share, with a total value of $343,800.00.
  • On Friday, May 18th, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The stock was purchased at an average cost of $4.04 per share, with a total value of $404,000.00.
  • On Friday, May 4th, Phillip Md Et Al Frost acquired 26,000 shares of OPKO Health stock. The stock was purchased at an average cost of $3.14 per share, with a total value of $81,640.00.
  • On Wednesday, May 2nd, Phillip Md Et Al Frost acquired 50,330 shares of OPKO Health stock. The stock was purchased at an average cost of $3.15 per share, with a total value of $158,539.50.
  • On Monday, April 30th, Phillip Md Et Al Frost acquired 75,000 shares of OPKO Health stock. The stock was purchased at an average cost of $3.08 per share, with a total value of $231,000.00.

Shares of OPKO Health opened at $4.40 on Monday, according to MarketBeat. OPKO Health has a 52-week low of $2.66 and a 52-week high of $7.25. The stock has a market capitalization of $2.46 billion, a PE ratio of -15.17 and a beta of 1.67. The company has a current ratio of 1.10, a quick ratio of 0.94 and a debt-to-equity ratio of 0.03.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.05. OPKO Health had a negative return on equity of 8.76% and a negative net margin of 31.27%. The business had revenue of $254.90 million for the quarter, compared to analyst estimates of $236.90 million. During the same quarter last year, the firm earned ($0.06) EPS. OPKO Health’s revenue for the quarter was down 4.3% compared to the same quarter last year. research analysts predict that OPKO Health will post -0.27 earnings per share for the current fiscal year.

A number of research firms have weighed in on OPK. Barrington Research reaffirmed a “buy” rating and issued a $7.00 price objective on shares of OPKO Health in a report on Wednesday, May 9th. ValuEngine raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Zacks Investment Research cut shares of OPKO Health from a “buy” rating to a “hold” rating in a report on Friday, May 25th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 price objective on shares of OPKO Health in a report on Tuesday, May 8th. Finally, BidaskClub raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Saturday, May 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. OPKO Health has an average rating of “Hold” and an average price target of $10.21.

A number of hedge funds have recently bought and sold shares of OPK. ING Groep NV grew its stake in OPKO Health by 121.2% in the fourth quarter. ING Groep NV now owns 71,168 shares of the biotechnology company’s stock valued at $349,000 after purchasing an additional 39,000 shares in the last quarter. Teacher Retirement System of Texas grew its stake in OPKO Health by 303.8% in the fourth quarter. Teacher Retirement System of Texas now owns 112,657 shares of the biotechnology company’s stock valued at $552,000 after purchasing an additional 84,759 shares in the last quarter. California Public Employees Retirement System grew its stake in OPKO Health by 2.8% in the fourth quarter. California Public Employees Retirement System now owns 811,356 shares of the biotechnology company’s stock valued at $3,976,000 after purchasing an additional 22,200 shares in the last quarter. First Trust Advisors LP bought a new position in OPKO Health in the fourth quarter valued at approximately $154,000. Finally, UBS Asset Management Americas Inc. grew its stake in OPKO Health by 17.1% in the fourth quarter. UBS Asset Management Americas Inc. now owns 277,534 shares of the biotechnology company’s stock valued at $1,360,000 after purchasing an additional 40,626 shares in the last quarter. Hedge funds and other institutional investors own 23.81% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.